CN Patent

CN114728932B — 作为egfr激酶抑制剂的多芳基化合物

Assigned to Jiangsu Simcere Pharmaceutical Co Ltd · Expires 2024-11-29 · 1y expired

What this patent protects

本发明涉及作为第四代(T790M/C797S突变)EGFR激酶抑制剂及其医药用途，具体公开了式(I)所示化合物或其药学上可接受的盐。本发明化合物在EGFR Del19/T790M/C797S和L858R/T790M/C797S异常突变引起的疾病上有着较好的疗效。

USPTO Abstract

本发明涉及作为第四代(T790M/C797S突变)EGFR激酶抑制剂及其医药用途，具体公开了式(I)所示化合物或其药学上可接受的盐。本发明化合物在EGFR Del19/T790M/C797S和L858R/T790M/C797S异常突变引起的疾病上有着较好的疗效。

Drugs covered by this patent

Alunbrig (brigatinib) · Takeda

Patent Metadata

Patent number: CN114728932B
Jurisdiction: CN
Classification: —
Expires: 2024-11-29
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Simcere Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.